Company Filing History:
3 out of 272 
2 out of 215 
1 out of 2 Years Active: 2006-2010
Title: Richard A Goldsby: Innovator in Transgenic Ungulate Research
Introduction
Richard A Goldsby is a notable inventor based in Leverett, MA (US). He has made significant contributions to the field of biotechnology, particularly in the production of transgenic ungulates. With a total of 5 patents, his work focuses on innovative methods that have the potential to revolutionize therapeutic applications in humans.
Latest Patents
Goldsby's latest patents include groundbreaking inventions such as the production of ungulates, preferably bovines, that produce human immunoglobulins. This invention relates to a method of producing ungulates with specific gene eliminations that prevent the development of native B- or T-cells. Consequently, these animals can accept human hematopoietic stem cell preparations, allowing for the injection of human B- and T-lymphocytes that produce human immunoglobulin for therapeutic uses. Another significant patent involves the creation of transgenic ungulates capable of producing large quantities of xenogenous antibodies, particularly human antibodies. This is achieved through the inactivation of IgM heavy chain expression and the introduction of an artificial chromosome that facilitates the expression of these antibodies.
Career Highlights
Throughout his career, Goldsby has worked with prominent companies in the biotechnology sector, including Kyowa Hakko Kirin Co., Limited and Kirin Beer Kabushiki Kaisha. His expertise in genetic engineering and immunology has positioned him as a leader in his field.
Collaborations
Goldsby has collaborated with esteemed colleagues such as James M Robl and Yoshimi Kuroiwa. These partnerships have further advanced his research and contributed to the development of innovative solutions in biotechnology.
Conclusion
Richard A Goldsby is a pioneering inventor whose work in transgenic ungulates has the potential to significantly impact therapeutic applications. His innovative patents and collaborations highlight his commitment to advancing biotechnology for human health.